This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (17)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Endophthalmitis  • Alert me on articles by topic

Franco M. Recchia, MD; Brandon G. Busbee, MD; Robert B. Pearlman, MD; Cynthia A. Carvalho-Recchia, MD; Allen C. Ho, MD

Arch Ophthalmol. 2005;123:341-346.

Objective  To analyze the microbiologic spectrum and in vitro susceptibility profiles over the last 11 years of organisms isolated from the vitreous of patients with endophthalmitis following cataract surgery.

Methods  Records of 497 consecutive patients treated at 1 institution for clinically suspected endophthalmitis following cataract surgery from July 1989 through June 2000 were reviewed. Results of microbiologic culture and in vitro antibiotic susceptibility testing from the periods 1989 to 1994 and 1995 to 2000 were compared.

Results  Between the 2 periods, there was a significant increase in the incidence of gram-positive bacteria (92%-97% of bacterial isolates). There was a significant increase in resistance among all bacterial isolates to ciprofloxacin (23%-37%; P = .02). There was increased resistance among coagulase-negative staphylococci to both ciprofloxacin (20%-38%) and cefazolin (19%-40%). Resistance to bacitracin, trimethoprim-sulfamethoxazole, and vancomycin remained unchanged. Vancomycin retained in vitro efficacy against more than 99% of gram-positive bacteria. Ceftazidime was effective against 100% of gram-negative bacteria tested.

Conclusions  The spectrum of pathogens causing postcataract endophthalmitis is changing, and resistance to antibiotics used for its prophylaxis has grown. These findings may affect the empirical treatment of postcataract endophthalmitis, as well as the use and choice of antibiotics in patients undergoing cataract surgery.

Author Affiliations: Division of Vitreoretinal Diseases and Surgery, Vanderbilt Eye Institute, Nashville, Tenn (Drs Recchia and Carvalho-Recchia); New England Eye Center, Boston, Mass (Dr Busbee); Department of Ophthalmology, Northwestern University School of Medicine, Chicago, Ill (Dr Pearlman); Retina Service, Wills Eye Hospital, Philadelphia, Pa (Dr Ho).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Bactericidal effect of intravitreal levofloxacin in an experimental model of endophthalmitis
Ferrer et al.
Br. J. Ophthalmol. 2008;92:678-682.
ABSTRACT | FULL TEXT  

Toward Improving Therapeutic Regimens for Bacillus Endophthalmitis
Wiskur et al.
IOVS 2008;49:1480-1487.
ABSTRACT | FULL TEXT  

Postoperative Vancomycin-Resistant Enterococcus faecium Endophthalmitis
Bains et al.
Arch Ophthalmol 2007;125:1292-1293.
FULL TEXT